|
|||
|
Home > News : Publications | ||
|
|||
|
|
|
|
Publications
Positive results in inflammatory eye disease treatment
http://www.swissbiotech.org/news/xigen%E2%80%99s-brimapitide-innovative-jnk-inhibitor-delivers-positive-phase-ii-results-inflammatory
https://scrip.pharmamedtechbi.com/SC097980/Xigens-PhII-Success-In-Ocular-Inflammation-Opens-Doors
Xigen’s Brimapitide, an innovative JNK inhibitor, delivers positive Phase II results in inflammatory eye disease. (PDF, 268 Kb)
https://scrip.pharmamedtechbi.com/SC097980/Xigens-PhII-Success-In-Ocular-Inflammation-Opens-Doors
Xigen’s Brimapitide, an innovative JNK inhibitor, delivers positive Phase II results in inflammatory eye disease. (PDF, 268 Kb)
Auris Medical Achieves Midpoint for Enrollment in Phase 3 Trial of AM-111 in Sudden Deafness
ZUG, Switzerland, Sept. 9, 2016 (GLOBE NEWSWIRE)
Dual kinase inhibition affords extended in vitro neuroprotection in Aβ toxicity
Gourmaud et al, Journal of Alzheimer’s Disease, 2016, PMID: 27636848
The present study show that PKR (double-stranded RNA dependent kinase) and c-Jun N-terminal kinase (JNK) pathways are actively activated in Aβ-induced neurotoxicity in neuronal cultures and that the dual inhibition of PKR and JNK (using XG-102 and XG-104) nearly completely blocked neuronal death in vitro.
https://www.ncbi.nlm.nih.gov/pubmed/27636848
The present study show that PKR (double-stranded RNA dependent kinase) and c-Jun N-terminal kinase (JNK) pathways are actively activated in Aβ-induced neurotoxicity in neuronal cultures and that the dual inhibition of PKR and JNK (using XG-102 and XG-104) nearly completely blocked neuronal death in vitro.
https://www.ncbi.nlm.nih.gov/pubmed/27636848
Auris Medical secures CHF 47.1 mn Series C financing from Sofinnova Ventures and Sofinnova Partners to advance ground-breaking inner ear therapies through Phase III clinical development
